CD19 and B-cell chronic lymphocytic leukemia: In hematological malignancies, anti-CD19 CAR-NK-92 cells improved cytotoxicity against leukemia cells and non-Hodgkin’s lymphoma or chronic lymphocytic leukemia (CLL) expressing CD19 (98, 99).